ライフサイエンスコーパス: meningococcal vaccine

1 nactivated influenza vaccine or quadrivalent meningococcal vaccine.

2 support for inclusion of this molecule in a meningococcal vaccine.

3 ingitidis serogroups included in the current meningococcal vaccine.

4 articipants who received a randomly assigned meningococcal vaccine.

5 rvations support the incorporation of Opa in meningococcal vaccines.

6 ructure that may affect the effectiveness of meningococcal vaccines.

7 lopment not only for gonorrhoea but also for meningococcal vaccines.

8 al, Haemophilus influenzae type b (Hib), and meningococcal vaccines.

9 ome outer membrane protein-based serogroup B meningococcal vaccines.

10 ing challenges for real-world evaluations of meningococcal vaccines.

11 d as a surface-exposed candidate antigen for meningococcal vaccines.

12 All infants received the meningococcal vaccine 8 months after being randomly assi

13 -vaccine era, use of a polyvalent conjugated meningococcal vaccine, and influenza vaccination during

14 immunological cross-reactivity of different meningococcal vaccine antigen variants.

15 s to factor H (fH)-binding protein (fHBP), a meningococcal vaccine antigen, activate classical comple

16 The meningococcal vaccine antigen, factor H (FH)-binding pro

17 tibody production in mice and is a candidate meningococcal vaccine antigen.

18 eful characteristic for an effective group B meningococcal vaccine antigen.

19 Other group B meningococcal vaccines are in development.

20 Combined with evidence that two meningococcal vaccines are likely partially protective a

21 New meningococcal vaccines are undergoing clinical trials, a

22 rs, and all other trial staff were masked to meningococcal vaccine assignments.

23 Patients received meningococcal vaccine at a screening visit and 2 weeks l

24 enrolled and randomly assigned to receive a meningococcal vaccine at either age 9 months (n=602) or

25 .2) at their 9-month EPI visits to receive a meningococcal vaccine at either their 9-month or 15-mont

26 view aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N. meningit

27 , and Feb 6, 2023, 600 participants received meningococcal vaccines at their 15-month visits.

28 ity to N. gonorrhoeae of serum raised to the meningococcal vaccine Bexsero, which contains the MeNZB

29 The meningococcal vaccine candidate factor H binding protein

30 The meningococcal vaccine candidate factor H-binding protein

31 Genome-derived neisserial Ag (GNA) 1870 is a meningococcal vaccine candidate that can be subdivided i

32 Factor H-binding protein (fHbp) is a novel meningococcal vaccine candidate that elicits serum antib

33 embrane protein previously investigated as a meningococcal vaccine candidate.

34 rrently under evaluation as a broad-spectrum meningococcal vaccine candidate.

35 proteins that have been considered potential meningococcal vaccine candidates.

36 te that molecular mimetics have potential as meningococcal vaccine candidates.

37 The older meningococcal vaccine, composed of capsular polysacchari

38 tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to diphtheria toxoid at

39 Meningococcal vaccines containing factor H binding prote

40 ived 3 doses of outer-membrane protein (OMP) meningococcal vaccine developed in either Cuba or Norway

41 creased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns

42 No patients reported previous meningococcal vaccine exposure.

43 and cerebrospinal fluid (CSF) samples from a meningococcal vaccine field trial performed in Iquique,

44 Use of the quadrivalent meningococcal vaccine for control of outbreaks has incre

45 a demonstrate the feasibility of preparing a meningococcal vaccine from a single recombinant protein

46 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).

47 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri

48 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina

49 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6

50 round the world, and a hexavalent PorA-based meningococcal vaccine has recently been developed in The

51 A significant problem in efficacy trials of meningococcal vaccines has been accurate identification

52 New conjugate meningococcal vaccines have successfully reduced endemic

53 e candidates in the search for comprehensive meningococcal vaccines; however, the formulation of OMP

54 p vaccine), meningococcal disease (conjugate meningococcal vaccine), human papillomavirus (for female

55 Traditionally, meningococcal vaccine impact is evaluated by predicting

56 re potentially preventable with the licensed meningococcal vaccine in 82.8% of 15 through 24 year old

57 n in patients on biologics, pneumococcal and meningococcal vaccines in adult patients without risk fa

58 llenge will be effective introduction of new meningococcal vaccines into developing countries, especi

59 The presently licensed meningococcal vaccine is a tetravalent capsular polysacc

60 Herd protection by meningococcal vaccines is conferred by population-level

61 Assessment of new serogroup B meningococcal vaccines is hampered by a scarcity of data

62 Observational evidence suggests the 4CMenB meningococcal vaccine may partially protect against gono

63 opose that outer membrane vesicle-containing meningococcal vaccines may be more efficacious if purged

64 -OMVs as adjuvants or as portions of group B meningococcal vaccines may help improve survival and out

65 in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C).

66 ng protein (fHbp; a key component of group B meningococcal vaccines) molecule.

67 d influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).

68 ve either an influenza vaccine or a control (meningococcal vaccine, pneumococcal vaccine, or placebo)

69 families and cost-effectiveness analyses for meningococcal vaccine programs.

70 The group A meningococcal vaccine (PsA-TT) clinical development plan

71 During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll

72 The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis be

73 hat for serogroups prevented by quadrivalent meningococcal vaccines, public health response to outbre

74 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w

75 ticipants receiving ViTT, ViPS, or a control meningococcal vaccine.RESULTSTranscriptomic responses re

76 In 2005, a new meningococcal vaccine, tetravalent meningococcal conjuga

77 was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac

78 ongoing to develop a serogroup B vaccine and meningococcal vaccines that are immunogenic in infants a

79 Meningococcal vaccines that target both NspA and FHbp ar

80 -19, or previously received capsular group B meningococcal vaccine (the control), were randomly assig

81 A conjugate group A meningococcal vaccine to prevent epidemics of meningitis

82 d diagnostic of disease in future testing of meningococcal vaccines to improve efficacy analyses.

83 A 'tailor-made' group B meningococcal vaccine was successfully used to control a

84 Children and adult recipients of either meningococcal vaccine were more likely than controls to

85 Meningococcal vaccines were administered to 600 of the 6

86 The meningococcal vaccines were co-administered with a measl

87 vels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled tri

88 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis

89 se data suggest that neither serogroup B OMP meningococcal vaccine would confer protection during a h